实时更新： Extrawell Pharmaceutical [0858.HK]

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.